News
NGENF
4.500
0.00%
0.000
NervGen Pharma Files SEC Registration to Advance Strategic Growth
TipRanks · 1d ago
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS
Newsfile · 1d ago
NERVGEN PHARMA CORP FILES FOR MIXED SHELF OF UP TO $150 MLN – SEC FILING
Reuters · 1d ago
Weekly Report: what happened at NGENF last week (1208-1212)?
Weekly Report · 4d ago
NervGen Pharma Proposes Amendment to Warrant Terms
TipRanks · 6d ago
NervGen Pharma Announces Proposed Amendment to Warrants
Newsfile · 6d ago
NERVGEN PHARMA CORP <NGEN.V>: RAYMOND JAMES RAISES TARGET PRICE TO C$8.00 FROM C$6.00
Reuters · 12/11 12:36
CANADA RESEARCH ROUNDUP-BCE, Capital Power, Telus
Reuters · 12/11 12:21
Weekly Report: what happened at NGENF last week (1201-1205)?
Weekly Report · 12/08 09:06
Weekly Report: what happened at NGENF last week (1124-1128)?
Weekly Report · 12/01 09:06
NervGen Pharma Advances NVG-291 for Spinal Cord Injury Treatment
TipRanks · 11/24 12:44
NervGen Pharma’s NVG-291 Shows Promising Results in Spinal Cord Injury Treatment
TipRanks · 11/24 12:42
NervGen Pharma GAAP EPS of -$0.06
Seeking Alpha · 11/24 12:22
NervGen Pharma Unveils Breakthrough Therapy Targeting Spinal Cord Injury Repair
Reuters · 11/24 12:06
NervGen Pharma Corp. Raises US$10 Million in Private Placement
Reuters · 11/24 12:05
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates
Newsfile · 11/24 12:05
NervGen Pharma Reports NVG-291 Achieves Durable Functional Gains in Chronic Spinal Cord Injury Trial
Reuters · 11/24 12:02
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury
Newsfile · 11/24 12:00
Weekly Report: what happened at NGENF last week (1117-1121)?
Weekly Report · 11/24 09:06
NervGen Pharma Secures $10M to Propel Nasdaq Listing and NVG-291 Development
TipRanks · 11/19 22:11
More
Webull provides a variety of real-time NGENF stock news. You can receive the latest news about Nervgen Pharma Corp through multiple platforms. This information may help you make smarter investment decisions.
About NGENF
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.